haematology
Bleeding disorders

Emicizumab to be funded for people with haemophilia A

Emicizumab  (Hemlibra) is expected to be available free of charge for people with haemophilia A by December 2020. The treatment, which without subsidy costs around over $675,000 per year, will be available for prophylaxis through the National Blood Authority (NBA) under a joint funding agreement between Federal and state governments. About 800 patients are expected to ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic